Search clinical trials for: chidamide and toripalimab

Total 271845 results

Shandong University

Not yet recruiting

A Multicenter Randomized Open-label Study of Chidamide Plus HD-DEX Versus HD-DEX in ITP

Thrombocytopenia
The First Affiliated Hospital of Soochow University

Recruiting

Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients

Multiple Myeloma

China
Qingdao University

Unknown

Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma (PET: Prednisone, Etoposide and Thalidomide) (PET)

Angioimmunoblastic T-cell Lymphoma

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

The Recombinant Humanized Anti-TIGIT Monoclonal Antibody (JS006) Monotherapy and in Combination With Toripalimab in Patients With Advanced Tumor

Advanced Tumors

China
Coherus Biosciences, Inc.

Recruiting

Study of CHS-114 in Participants With Advanced Solid Tumors

Advanced Solid Tumor | Head and Neck Squamous Cell Carcinoma

United States
Ge Zheng

Recruiting

Study of Chidamide Combined With Cladribine in Refractory/Relapsed Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
United BioPharma

Completed

A Proof-of-concept Trial to Evaluate the Safety and Efficacy of UB-421 Plus Chidamide in Changing HIV Reservoirs

HIV-1 Infection

Taiwan
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Toripalimab for High-risk Locally Advanced Cervical Cancer

Cervical Cancers

China
First Affiliated Hospital of Zhejiang University
Shanghai Longfine Biotechnology Co., Ltd.; TopAlliance

Not yet recruiting

A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.

Triple-negative Breast Cancer

China
Nanfang Hospital, Southern Medical University

Not yet recruiting

Toripalimab Maintenance for Locally Advanced Head and Neck Squamous Cell Carcinoma

Locally Advanced Head and Neck Squamous Cell Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Active, not recruiting

Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma

Unresectable Hepatocellular Carcinoma

China
China Medical University, China
Beijing Bio-Targeting Therapeutics Technology Co., Ltd

Not yet recruiting

A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer

Gastric Cancer, Metastatic
Peking University

Unknown

Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)

B-cell Non-Hodgkin's Lymphoma
Chinese PLA General Hospital

Unknown

Decitabine-primed Tandem CD19/CD20 CAR T Cells Plus Epigenetic Agents in Aggressive r/r B-NHL With Huge Tumor Burden

Refractory or Relapsed Aggressive r/r B-NHL With Huge Tumor Burden

China
Sun Yat-sen University
Xiangya Hospital of Central South University; Wuhan University; Zhujiang Hospital and other collaborators

Recruiting

Consolidation of Toripalimab After Chemoradiotherapy in Elderly Esophageal Cancer (EC-CRT-007) (EC-CRT-007)

Locally Advanced Esophageal Squamous Cell Carcinoma

China
Winston Laboratories

Completed

Evaluation of Civamide Patch in Treatment of Postherpetic Neuralgia and Post-Incisional Neuralgia

Postherpetic Neuralgia

United States, Canada
West China Hospital

Recruiting

Neoadjuvant Therapy for Locally Advanced Rectal Cancer With Fruquintinib, Toripalimab and SRT

Rectal Cancer

China
First Affiliated Hospital of Zhejiang University

Unknown

Chidamide With R-CHOP Regimen for DLBCL Patients (DLBCL)

Diffuse Large B Cell Lymphoma

China
Shanghai Ninth People's Hospital Affiliated to...

Recruiting

Neoadjuvant and Adjuvant Toripalimab and Cetuximab in Patients With Recurrent, Resectable Squamous Cell Carcinoma of Head and Neck: a Prospective, Single-arm,Phase II Study

Patients With Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Neoadjuvant Toripalimab or Toripalimab in Combination With Carboplatin and Nab-paclitaxel in Untreated HNSCC (HNSCC-002)

Head and Neck Squamous Cell Carcinoma

China
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)

Non Small Cell Lung Cancer Recurrent
Sun Yat-sen University

Recruiting

Toripalimab With or Without Celecoxib as Neoadjuvant Therapy in Resectable dMMR/MSI-H Colorectal Cancer (PICC)

Colorectal Cancer | Neoadjuvant Therapy | Mismatch Repair-deficient (dMMR) | Microsatellite Instability-high (MSI-H)

China
Di Wu

Not yet recruiting

Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma

Undifferentiated Pleomorphic Sarcoma | Soft Tissue Sarcomas

China
Peking Union Medical College Hospital
Beijing Longfu Hospital

Not yet recruiting

Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell Lymphoma

Angioimmunoblastic T-cell Lymphoma

China
Yongchang Zhang

Completed

Toripalimab Combined With Double Platinum Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer

Advanced Non Small Cell Lung Cancer

China
Chipscreen Biosciences, Ltd.

Completed

Trial of Chidamide in Combination With Exemestane in Patients With Advanced Breast Cancer

Breast Cancer

China
Nanfang Hospital of Southern Medical University

Recruiting

Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL

Leukemia | Leukemia, B-cell | Leukemia, Acute | Leukemia, Lymphoblastic

China
Winston Laboratories

Completed

A Phase III Study of Civamide Nasal Solution (Zucapsaicin) for the Treatment of Episodic Cluster Headache

Episodic Cluster Headache

United States
Xiangya Hospital of Central South University

Recruiting

Adjuvant Immunotherapy With Toripalimab Following Curative-intent Ablation for Recurrent Hepatocarcinoma

Hepatocellular Carcinoma

China
Zhejiang Cancer Hospital

Recruiting

Clinical Study on the First-line Treatment of Advanced Biliary System Tumors With Tripley Monoclonal Antibody Combined With GEMOX Regimen

Advanced Biliary Tract Tumors

China
UBP Greater China (Shanghai) Co., Ltd

Not yet recruiting

A Proof of Concept Study to Evaluate the Effect of UB-421 in Combination With Chidamide on HIV Viral Reservoir

HIV-1-infection
Sichuan University

Unknown

Tofacitinib Combined With Chidamide in R/R ENKTCL

Extranodal NK/T-cell Lymphoma

China
Jiangsu Cancer Institute & Hospital

Recruiting

Short Course Neoadjuvant Chemo-radiotherapy Plus Toripalimab for Locally Advanced Resectble Squamous Cell Carcinoma of Esophagus (SCALE-2)

Locally Advanced Esophageal Carcinoma

China
Sun Yat-sen University
Wuzhou Red Cross Hospital; Fifth Affiliated Hospital, Sun Yat-Sen University; Affiliated Cancer Hospital & Institute of Guangzhou Medical University and other collaborators

Recruiting

Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Chemotherapy | Radiotherapy | PD-1 Treatment

China
Sun Yat-sen University

Active, not recruiting

Phase II Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Combined With CCRT in NPC Patients

Nasopharyngeal Carcinoma

China
Shouyao Holdings (Beijing) Co. LTD

Recruiting

Safety, Pharmacokinetics and Efficacy of CT-707, Toripalimab and Gemcitabine in Advanced Pancreatic Cancer

Advanced Pancreatic Cancer

China
Fudan University

Recruiting

Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT

Nasopharyngeal Cancer

China
wang shusen

Recruiting

Tucidinostat and Metronomic Capecitabine for Metastatic Triple-negative Breast Cancer:a Multicenter,Open-label, Randomized Controlled, Phase II Clinical Trial

Triple Negative Breast Cancer

China
Ruijin Hospital

Recruiting

Azacitidine Combined With Chidamide in the Treatment of Newly Diagnosed PTCL Unfit for Conventional Chemotherapy

Peripheral T-cell Lymphoma

China
Institute of Hematology & Blood Diseases Hospital

Recruiting

Chidamide Plus Azacitidine for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma

Peripheral T Cell Lymphoma | Epigenetic Repression

China
TJ Biopharma Co., Ltd.

Active, not recruiting

A Phase I/II Study of TJ004309 for Advanced Solid Tumor

Advanced Solid Tumor

China
Sun Yat-sen University

Recruiting

Safety and Efficacy of RX-af01 Combined With PD-1 Antibody

Solid Tumor | Intestinal Flora | Immune Checkpoint Inhibitor

China
Sun Yat-sen University
Guangdong Provincial Hospital of Traditional Chinese Medicine; Fujian Cancer... and other collaborators

Recruiting

PD-1 Antibody for The Prevention of Adenomatous Polyps and Second Primary Tumors in Lynch Syndrome Patients

Lynch Syndrome

China
Winston Laboratories

Terminated

Oral Civamide Safety, Tolerability First in Human Study

Healthy

United States
Guangdong Provincial People's Hospital
Shenzhen Chipscreen Biosciences Co.Ltd

Recruiting

A Study of Chidamide With AZA in MRD Positive AML After Transplant

Minimal Residual Disease | AML, Adult

China
Shanghai Junshi Bioscience Co., Ltd.

Withdrawn

A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies

Primary Condition: Advanced Tumors

China
Chinese PLA General Hospital

Recruiting

Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma

Hodgkin Lymphoma

China
Sun Yat-sen University

Recruiting

Toripalimab Combined With CAV/IE Regimen

Soft Tissue Sarcoma

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer

Recurrent or Metastatic NPC

China, Taiwan, Singapore
Institute of Hematology & Blood Diseases Hospital...

Not yet recruiting

Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia | AML

3

Subscribe